From Wikipedia, the free encyclopedia
  (Redirected from PRC200)
Jump to navigation Jump to search
PRC200 structure.png
CAS Number
PubChem CID
ECHA InfoCard100.207.294 Edit this at Wikidata
Chemical and physical data
Molar mass291.394 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.


  1. ^ Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R.; Richelson, E. (2008). "Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–583. doi:10.1124/jpet.108.143610.
  2. ^ "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. ^ Guha, Mausumee; Heier, Annabelle; Price, Sally; Bielenstein, Margareta; Caccese, Robert G.; Heathcote, Daniel I.; Simpson, Thomas R.; Stong, David B.; Bodes, Elmarie (2011). "Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor". Toxicological Sciences. 120 (2): 269–283. doi:10.1093/toxsci/kfr013.